Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi

Drug Profile

Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi

Alternative Names: AD Combination hydrocodone; AD ER hydrocodone; Hydrocodone controlled release - Egalet/Shionogi

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egalet
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Pain in Japan (PO, Controlled release)
  • 20 Dec 2017 Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi is available for licensing as of 20 Dec 2017. http://egalet.com/
  • 05 Jun 2017 Egalet has patent protection for GuardianTM Technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top